Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23424122 | 0.80 | HMGCR (0.36) | HMGCRCHRM1TBXA2RADRA1AKMT2A | |
| SCHEMBL13543290 | 0.78 | HMGCR (0.41) | HMGCRCHRM1TBXA2RADRA1AKMT2A | |
| SCHEMBL8460026 | 0.77 | HMGCR (0.31) | HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL13554238 | 0.75 | HMGCR (0.33) | HMGCRCHRM1TBXA2RADRA1ATSHR | |
| SCHEMBL11993633 | 0.75 | KMT2A (0.33) | HMGCRCHRM1TBXA2RADRA1AKMT2A | |
| SCHEMBL25007292 | 0.75 | FAAH (0.42) | KMT2A | |
| SCHEMBL8406316 | 0.75 | KMT2A (0.33) | HMGCRCHRM1TBXA2RADRA1AKMT2A | |
| SCHEMBL8962260 | 0.75 | HMGCR (0.33) | HMGCRCHRM1TBXA2RADRA1AKMT2A | |
| SCHEMBL2905419 | 0.73 | TSHR (0.42) | HMGCRCHRM1TBXA2RADRA1AKMT2A | |
| SCHEMBL20428537 | 0.73 | HMGCR (0.32) | HMGCRCHRM1TBXA2RADRA1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024256780-A1 | COMPOSITION COMPRISING PVDF AND USE THEREOF FOR PREPARING AN ELECTRODE | ARKEMA FRANCE (FR) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024149954-A1 | COMPOSITION FOR ALL-SOLID-STATE BATTERY, AND FILM PREPARED THEREFROM | ARKEMA FRANCE (FR) | 2024-07-18 | — | — | WO | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-12019371-B2 | Photosensitive composition, film, color filter, solid-state imaging element, and image display device | FUJIFILM CORPORATION (JP) | 2024-06-25 | — | — | US | disclosed |
| US-12016903-B2 | Long-acting growth hormone treatment | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2024-06-25 | — | — | US | disclosed |
| WO-2024110734-A1 | METHOD FOR PREPARING A HALOGENATED POLYMER VIA DEHYDROHALOGENATION | ARKEMA FRANCE (FR) | 2024-05-30 | — | — | WO | disclosed |
| US-20240066141-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | FIREFLY BIO, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240024494-A1 | SMALL-MOLECULE CONJUGATE AND USE THEREOF | ANHUI CHINA RESOURCES JINCHAN PHARMACEUTICAL CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-7342016-B2 | Farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-7291618-B2 | Therapeutic compounds | PFIZER INC (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070213315-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-13 | — | — | US | disclosed |
| US-20070161664-A1 | THERAPEUTIC COMPOUNDS | PFIZER INC | 2007-07-12 | — | — | US | disclosed |
| US-20070099897-A1 | Therapeutic compounds | PFIZER INC | 2007-05-03 | — | — | US | disclosed |
| US-7199265-B2 | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones | KARO BIO AB (SE) | 2007-04-03 | — | — | US | disclosed |
| US-7192979-B2 | EP4 receptor selective agonist in the treatment of osteoporosis | PFIZER INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070054837-A1 | Bicyclic lactones, perfumery uses thereof, processes for preparing same and intermediates therefor | INTERNATIONAL FLAVORS & FRAGRANCES INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070032437-A1 | that bind cellular inhibitor of apoptosis proteins; drug design and development for diagnosis, prevention and treatment of cell proliferative disease; anticarcinogenic agents | THE TRUSTEES OF PRINCETON UNIVERSITY | 2007-02-08 | — | — | US | disclosed |
| US-7169747-B2 | Bicyclic lactones, perfumery uses thereof, processes for preparing same and intermediates therefor | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099897-A1 | Therapeutic compounds | SLC5A2, SLC5A1, REN | HMGCR 328/4885CHRM1 988/4885TBXA2R 74/4885 |
| US-20070213315-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | HMGCR 686/4885CHRM1 6/4885TBXA2R 48/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | HMGCR 3590/4885CHRM1 4416/4885TBXA2R 4429/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | HMGCR 978/4885CHRM1 1642/4885TBXA2R 165/4885 |
| US-12016903-B2 | Long-acting growth hormone treatment | GHRHR, GHSR, GHITM | HMGCR 379/4885CHRM1 4855/4885TBXA2R 2213/4885 |
| US-20240066141-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | CD44, EPCAM, MSN | HMGCR 2201/4885CHRM1 2645/4885TBXA2R 2515/4885 |
| US-20070161664-A1 | THERAPEUTIC COMPOUNDS | SLC5A2, SLC5A1, REN | HMGCR 328/4885CHRM1 988/4885TBXA2R 74/4885 |
| US-20070032437-A1 | that bind cellular inhibitor of apoptosis proteins; drug design and development for diagnosis, prevention and treatment of cell proliferative disease; anticarcinogenic agents | BIRC3, API5, BID | HMGCR 3532/4885CHRM1 4333/4885TBXA2R 3831/4885 |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | TPX2, H1-4, MAPT | HMGCR 3765/4885CHRM1 39/4885TBXA2R 3578/4885 |
| US-20240024494-A1 | SMALL-MOLECULE CONJUGATE AND USE THEREOF | SLC7A5, SLC43A1, CD44 | HMGCR 1651/4885CHRM1 4164/4885TBXA2R 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.